Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis

ABSTRACT: Abstract

Objective

Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive and economically challenging for healthcare systems. Cost analyses of drugs against candidiasis, such as rezafungin, are thus of great interest to healthcare payers.

Methods

We conducted a cost-of-illness study of patients with Candida infections based on real-word data of the Department I of Internal Medicine, University Hospital Cologne (Germany) between 2016 and 2021. Health-economic parameters were analysed to describe the economic impact of Candida infections. Potential cost savings due to the administration of rezafungin were modelled for patients with invasive candidiasis or candidaemia based on a 5 day red

SUBMITTER:  

PROVIDER: S-EPMC10279419 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature